FDA’s Priority Review Voucher Program Can Be Used More Proactively To Improve Disease Outbreak Preparedness

Health Affairs Blog: To Improve Pandemic Preparedness, Update The Priority Review Voucher Program
Ken Gustavsen, executive director of corporate responsibility at Merck and senior vice president of the Merck Foundation, discusses how the FDA’s priority review voucher (PRV) program “could be used far more proactively to help address future pandemics before they strike. … [R]egularly reviewing the PRV [disease] list and revising it to include top potential threats would be a simple yet critical step in helping to improve the state of public health readiness to address the next pandemic…” (3/22).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.